Paper950324
Naturally-occurring beta-lactamase inhibitors with antibacterial activity.
Brown AG and 6 others. J Antibiot (Tokyo), 1976. Cited by 310 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. Naturally-occurring beta-lactamase inhibitors with antibacterial activity. Papers, record 950324. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950324
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amidohydrolases | Major topic |
| Anti-Bacterial Agents | Major topic |
| Bacteria | Major topic |
| beta-Lactamase Inhibitors | Major topic |
| beta-Lactams | Major topic |
| Enterobacteriaceae | |
| Streptomyces |
Source PubMed
Cited by85
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 310 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,515,775 | 1,8-Cineole Potentiates the Antibacterial Activity of Amoxicillin/Clavulanic Acid Against an ESBL-Producing Escherichia coli Strain: An In Vitro and In Silico Investigation. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42515775 | PubMed |
| 42,218,329 | Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosis. | NPJ Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42218329 | PubMed |
| 41,693,264 | Preclinical Pharmacokinetics and Pharmacodynamics of Antibiotic Adjuvants. | ACS Infect Dis | 2026 | https://conductscience.org/library/papers/41693264 | PubMed |
| 41,148,651 | Microalgae, Cell Factories for Antimicrobial Peptides: A Promising Response to Antibiotic Resistance. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41148651 | PubMed |
| 40,008,972 | Reflecting on Fleming's caveat: the impact of stakeholder decision-making on antimicrobial resistance evolution. | Microbiology (Reading) | 2025 | https://conductscience.org/library/papers/40008972 | PubMed |
| 40,001,427 | Comprehensive Overview of Antibacterial Drugs and Natural Antibacterial Compounds Found in Food Plants. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40001427 | PubMed |
| 39,975,665 | Dynamic kinetic resolution-mediated synthesis of C-3 hydroxylated arginine derivatives. | R Soc Open Sci | 2025 | https://conductscience.org/library/papers/39975665 | PubMed |
| 39,376,491 | Photoredox-catalyzed intramolecular nucleophilic amidation of alkenes with β-lactams. | Beilstein J Org Chem | 2024 | https://conductscience.org/library/papers/39376491 | PubMed |
| 38,075,910 | Streptomyces tamarix sp. nov.: antagonism against Alternaria gaisen producing streptochlorin, isolated from Tamarix root soil. | Front Microbiol | 2023 | https://conductscience.org/library/papers/38075910 | PubMed |
| 38,027,012 | Bibliometric insights into the most influential papers on antibiotic adjuvants: a comprehensive analysis. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38027012 | PubMed |
| 37,717,068 | Mycobacterium tuberculosis β-lactamase variant reduces sensitivity to ampicillin/avibactam in a zebrafish-Mycobacterium marinum model of tuberculosis. | Sci Rep | 2023 | https://conductscience.org/library/papers/37717068 | PubMed |
| 37,008,128 | Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance. | ACS Omega | 2023 | https://conductscience.org/library/papers/37008128 | PubMed |
| 35,628,478 | Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35628478 | PubMed |
| 34,860,516 | Prospects for Antibacterial Discovery and Development. | J Am Chem Soc | 2021 | https://conductscience.org/library/papers/34860516 | PubMed |
| 34,641,601 | Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and β-Lactams. | Molecules | 2021 | https://conductscience.org/library/papers/34641601 | PubMed |
| 34,436,106 | TCA Cycle and Its Relationship with Clavulanic Acid Production: A Further Interpretation by Using a Reduced Genome-Scale Metabolic Model of Streptomyces clavuligerus. | Bioengineering (Basel) | 2021 | https://conductscience.org/library/papers/34436106 | PubMed |
| 34,421,874 | Streptomyces tardus sp. nov.: A Slow-Growing Actinobacterium Producing Candicidin, Isolated From Sediments of the Trondheim Fjord. | Front Microbiol | 2021 | https://conductscience.org/library/papers/34421874 | PubMed |
| 34,239,861 | Robustifying Experimental Tracer Design for13C-Metabolic Flux Analysis. | Front Bioeng Biotechnol | 2021 | https://conductscience.org/library/papers/34239861 | PubMed |
| 33,688,218 | In vitro Effect of the Combination of Aztreonam and Amoxicillin/Clavulanic Acid Against Carbapenem-Resistant Gram-Negative Organisms Producing Metallo-β-Lactamase. | Infect Drug Resist | 2021 | https://conductscience.org/library/papers/33688218 | PubMed |
| 33,266,085 | Synergistic Effect of Propidium Iodide and Small Molecule Antibiotics with the Antimicrobial Peptide Dendrimer G3KL against Gram-Negative Bacteria. | Molecules | 2020 | https://conductscience.org/library/papers/33266085 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/950324
GET https://conductscience.org/api/papers/v1/950324/cited_by?page=2